Procedure
Selective lymph node dissection
Selective lymph node dissection is a medical procedure with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
PROCEDURE
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_3
1
33%
Ph not_applicable
2
67%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
N/ANon-phased studies
2(66.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 31 (33.3%)
N/A2 (66.7%)
Trials by Status
not_yet_recruiting133%
recruiting267%
Recent Activity
2 active trials
Showing 3 of 3
recruitingnot_applicable
Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm
NCT06634979
recruitingphase_3
Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)
NCT06031246
not_yet_recruitingnot_applicable
A Single-center Study on the Effect of Systemic/Selective Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With Components With Consolidation/Tumor Ratio Between 0.5-1
NCT05184829
Clinical Trials (3)
Showing 3 of 3 trials
NCT06634979Not Applicable
Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter of ≤ 2 cm
NCT06031246Phase 3
Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)
NCT05184829Not Applicable
A Single-center Study on the Effect of Systemic/Selective Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With Components With Consolidation/Tumor Ratio Between 0.5-1
All 3 trials loaded
Drug Details
- Intervention Type
- PROCEDURE
- Total Trials
- 3